Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: A cohort study

Autor: Wuling Ou, Fei Ming, Yu Qian, Shaozhong Wei, Sheng Hu, Gai Liang, Qian Cai, Jing Zhang, Weida Wang, Shuang Dong, Yiqun Hao
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
medicine.medical_specialty
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pneumonia
Viral
lcsh:Medicine
Comorbidity
Antibodies
Monoclonal
Humanized
Gastroenterology
General Biochemistry
Genetics and Molecular Biology
Betacoronavirus
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Tocilizumab
Internal medicine
medicine
Humans
Propensity Score
Interleukin 6
Pandemics
Aged
Retrospective Studies
biology
SARS-CoV-2
Interleukin-6
business.industry
Research
lcsh:R
COVID-19
Retrospective cohort study
General Medicine
Guideline
Middle Aged
medicine.disease
COVID-19 Drug Treatment
Kinetics
Treatment Outcome
030104 developmental biology
chemistry
030220 oncology & carcinogenesis
Propensity score matching
biology.protein
Female
Coronavirus Infections
business
Cohort study
Zdroj: Journal of Translational Medicine
Journal of Translational Medicine, Vol 18, Iss 1, Pp 1-8 (2020)
Popis: Background Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-19 patients, and report preliminary data on the efficacy of IL-6 receptor blockade. Methods We conducted a retrospective single-institutional study of 901 consecutive confirmed cases. Serum IL-6 concentrations were tested on admission and/or during hospital stay. Tocilizumab was given to 16 patients with elevated IL-6 concentration. Results 366 patients were defined as common cases, 411 patients as severe, and 124 patients as critical according to the Chinese guideline on diagnosis and treatment of COVID-19. The median concentration of IL-6 was P P P = 0.12). Conclusion Serum IL-6 should be included in diagnostic work-up to stratify disease severity, but the benefit of tocilizumab needs further confirmation. Trial registration retrospectively registered.
Databáze: OpenAIRE
Externí odkaz: